Glycemic Control with Apidra®
The Flexibility to be used in both type 1 and type 2
adult diabetes patients
Apidra® provides effective glycemic control
for type 2 diabetes patients
Comparable reductions in A1C vs RHI in type 2 diabetes patients (mean BMI=34.55)2,10
Mean change in A1C(%) from baseline* (N=876)2,10
A 26-week, randomized, open-label, active-control study compared Apidra
® with RHI given premeal (both groups were given intermediate-acting basal insulin twice daily; mean baseline A1C <7.6%).
² "Endpoint" was the last available measurement after start of treatment.
¹ Apidra
® or RHI was individually dosed as appropriate prior to at least 2 meals a day (breakfast and dinner).
¹ The mean number of daily short-acting insulininjections at endpoint was 2.27 for Apidra
® (n=404) and 2.24 for RHI (n=403).
² The mean BMI was 34.55 kg/m².
*The baseline A1C value was 7.57% for Apidra
® and 7.50% for RHI.
²
- Reductions from baseline were similar between both treatment groups2
- The clinical relevance of the differences in A1C reduction between RHI and Apidra® is unknown
- Efficacy was maintained regardless of presence or absence of oral hypoglycemic agent use10
Postprandial control achieved with both Apidra® and RHI in type 2 diabetes patients
- Significantly lower mean blood glucose levels from baseline at 2 hours postbreakfast and 2 hours postdinner10
- Apidra ® and RHI provided consistently low premeal blood glucose levels10
Apidra® provides effective glycemic control for type 1 diabetes patients
Equal reductions in A1C vs lispro in type 1 diabetes patients(mean BMI=24.99)1,2
Important Safety Information for Apidra®
Apidra® is indicated for the treatment of adult patients with diabetes mellitus
for the control of hyperglycemia.
Apidra® has a more rapid onset of action and a shorter duration of action than
regular human insulin. Apidra® should normally be used in regimens that include
a longer-acting insulin or basal insulin analog.
OptiClik® is a reusable insulin delivery device (insulin pen) for use with a
3-mL Apidra® cartridge (U-100). Needles and the OptiClik® pen must not be shared.
Apidra® is contraindicated during episodes of hypoglycemia and in patients hypersensitive
to Apidra® or one of its excipients.
Apidra® differs from regular human insulin by its rapid onset of action and shorter
duration of action. When used as a mealtime insulin, the dose of Apidra® should
be given within 15 minutes before or within 20 minutes after starting a meal.
Because of the short duration of action of Apidra®, patients with diabetes also
require a longer-acting insulin or insulin infusion pump therapy to maintain adequate
glucose control.
Any change of insulin should be made cautiously and only under medical supervision.
Changes in insulin strength may result in the need for a change in dose. Concomitant
oral antidiabetic treatment may need to be adjusted.
As with all insulin preparations, the time course of Apidra® action may vary
in different individuals or at different times in the same individual and is dependent
on site of injection, blood supply, temperature, and physical activity.
Glucose monitoring is recommended for all patients with diabetes.
Hypoglycemia is the most common adverse effect of insulin therapy, including Apidra®.
The timing of hypoglycemia may differ among various insulin formulations.
Adverse events commonly associated with human insulin therapy include hypoglycemia,
allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash.
Please click here for full prescribing information for Apidra®
